Clinical Trials Logo

Stage IA Ovarian Cancer clinical trials

View clinical trials related to Stage IA Ovarian Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03297489 Completed - Clinical trials for Primary Peritoneal Carcinoma

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Start date: November 6, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies how well intravital microscopy works in evaluating patients with primary peritoneal, fallopian tube, or stage IA-IV ovarian cancer. Intravital microscopic evaluation of tumor blood vessels, blood flow, immune cell interactions, and drug uptake may be eventually visualized and may lead to valuable prognostic information.

NCT ID: NCT03198286 Completed - Clinical trials for Stage IIIA Breast Cancer

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well the Carevive Survivor Care Planning System works in improving quality of life in breast cancer survivors. A personalized survivor care plan includes a summary of a patient's cancer treatment and a customized survivor care plan and may provide beneficial information and resources.

NCT ID: NCT01522820 Completed - Glioblastoma Clinical Trials

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.

NCT ID: NCT01080521 Completed - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Start date: April 2010
Phase:
Study type: Observational

This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy. Learning about the effects of chemotherapy on brain function may help doctors plan cancer treatments.

NCT ID: NCT00897442 Completed - Melanoma Clinical Trials

Collecting Tumor Samples From Patients With Gynecological Tumors

Start date: June 1992
Phase: N/A
Study type: Observational

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.

NCT ID: NCT00857545 Completed - Clinical trials for Stage IV Ovarian Cancer

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has decreased or disappeared, but the cancer may still be in the body. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether OPT-821 is more effective with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.